Takeda Patient Assistance Program & Other Resources

Support throughout the patient treatment journey

FREEDOM OF CHOICE™ free-trial program

Your patients may be eligible to receive 6 free-trial doses of ADVATE with the FREEDOM OF CHOICE trial program. The free-trial program is for new patients only. Participants must receive consultation and approval from their healthcare provider.

download form

Takeda Patient Services

— support specialists you can count on

Takeda Patient Services is a product support program for people who have been prescribed ADVATE and who are enrolled in a Takeda Patient Support Program. Our support specialists are here to address your questions and concerns and help get you the answers, resources, and tools you need. Some of the ways we can assist include:

Enrolling
you in a Takeda Patient Support Co-Pay Assistance Program if you qualify*
Working
with your specialty pharmacy (or site of care) to help you receive ADVATE
Arranging
for nursing support, if you have questions about your condition and ADVATE
Directing
you to community support resources and education
Providing
you with tips and timely information throughout your ADVATE treatment. We also provide insurance support by reviewing your coverage and helping you understand what financial options may be available

Want to connect?
Our support specialists are never more than a tap or a call away–
program phone number,
1-888-229-8379 Monday–Friday 8:30AM–8:00PM (ET).

Learn more about
Program Enrollment
VISIT HEMATOLOGYSUPPORTPRO.COM

*To be eligible, you must be enrolled in a Takeda Patient Support Program and have commercial insurance. Other terms and conditions apply. Call us for more details.

Resources for your patients

Goals worksheet

This worksheet can help patients track their ABR progress and start their journey striving toward zero bleeds.

Download worksheet

Bleed and infusion tracker

This tool can help patients track their bleeds and infusions so they can stay on top of their treatment management.

Download worksheet

ADVATE Stay the Course Brochure

ADVATE patients seeking encouragement to stay the course can reference this brochure, which contains helpful disease state education, product information, and supportive tips.

Download brochure

ADVATE Patient Profile

This brochure highlights Ezra, a real ADVATE patient, and how he manages his hemophilia A and stays dedicated to his factor regimen.

Download brochure

ADVATE [Antihemophilic Factor (Recombinant)] Important Information

Indications

ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:

Control and prevention of bleeding episodes.
Perioperative management.
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

CONTRAINDICATIONS

Patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product.

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with ADVATE. Symptoms include dizziness, paresthesia, rash, flushing, facial swelling, urticaria, dyspnea, pruritus, and vomiting. Discontinue ADVATE if hypersensitivity symptoms occur and administer appropriate emergency treatment.

Neutralizing Antibodies

Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

ADVERSE REACTIONS

Serious adverse reactions seen with ADVATE are hypersensitivity reactions, including anaphylaxis, and the development of high-titer inhibitors necessitating alternative treatments to factor VIII.
The most common adverse reactions observed in clinical trials (>5% of subjects) were pyrexia, headache, cough, nasopharyngitis, arthralgia, vomiting, upper respiratory tract infection, limb injury, nasal congestion, and diarrhea.

Click to read Full Prescribing Information.